Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase II randomised placebo-controlled double-blind multicentre trial

RATIONALE: Haematoma growth is common early after intracerebral haemorrhage (ICH), and is a key determinant of outcome. Tranexamic acid, a widely available antifibrinolytic agent with an excellent safety profile, may reduce haematoma growth. METHODS AND DESIGN: Stopping intracerebral haemorrhage wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Yassi, Nawaf, Zhao, Henry, Churilov, Leonid, Campbell, Bruce C V, Wu, Teddy, Ma, Henry, Cheung, Andrew, Kleinig, Timothy, Brown, Helen, Choi, Philip, Jeng, Jiann-Shing, Ranta, Annemarei, Wang, Hao-Kuang, Cloud, Geoffrey C, Grimley, Rohan, Shah, Darshan, Spratt, Neil, Cho, Der-Yang, Mahawish, Karim, Sanders, Lauren, Worthington, John, Clissold, Ben, Meretoja, Atte, Yogendrakumar, Vignan, Ton, Mai Duy, Dang, Duc Phuc, Phuong, Nguyen Thai My, Nguyen, Huy-Thang, Hsu, Chung Y, Sharma, Gagan, Mitchell, Peter J, Yan, Bernard, Parsons, Mark W, Levi, Christopher, Donnan, Geoffrey A, Davis, Stephen M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067256/
https://www.ncbi.nlm.nih.gov/pubmed/34848566
http://dx.doi.org/10.1136/svn-2021-001070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067256/
https://www.ncbi.nlm.nih.gov/pubmed/34848566
http://dx.doi.org/10.1136/svn-2021-001070

Ejemplares similares